NDAINHALATIONGAS
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
3/8 — Basic
NITROUS OXIDE, USP (nitrous oxide) by Advanced Solutions Life Sciences. Approved for anesthesia, sedation, pain and 1 more indications. First approved in 2017.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nitrous oxide (N₂O) is an inhaled gas used for anesthesia, sedation, and acute pain relief across dental, surgical, and procedural settings. It acts as a CNS depressant, reducing anxiety and pain perception while maintaining patient consciousness when used at sub-anesthetic doses. The drug is a well-established, legacy anesthetic with broad clinical utility in acute care.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%); team size and growth likely stable, with focus on market maintenance and utilization expansion rather than market share gains.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (4)
Worked on NITROUS OXIDE, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.